The present application is directed generally to labels, and more specifically to labels for consumer product containers that illustrate medical information related to medication in the container.
Containers for consumer products have a limited amount of outer surface area for placement of labels on the container. This may pose a challenge to manufacturers of these consumer products to fit all of the information they want to deliver to the consumer, or are required by law to deliver to the consumer, in this limited area. In particular, packaging for prescription medications may specify a significant amount of information concerning the condition the medication is intended to treat, as well as the effects of consuming the medication.
Manufacturers of pharmaceuticals and other medical-related packaged products spend millions of dollars each year explaining to consumers how their medication may provide relief for medical conditions. The means of delivery of this information, such as television advertisements, print advertisements, and additional on-package print material, can be very costly and serve to increase the cost of the medication to the consumer. All this effort may ultimately go to waste if the consumer does not take the initiative to seek out and read the information.
Health care professionals often inform patients of medical conditions and the importance of taking prescribed medications using charts and other visual aids. Visual aids may be easier to comprehend and lend themselves to be more readily remembered. However, over time patient may tend to forget the information presented on the visual aid because there is no reinforcement of the information after the patient leaves the office of the health care provider.
The present application is directed to rotating label medical information systems for a container. An exemplary illustrative rotating label medical information system may comprise a base label adhered to the container. The base label may have a back surface and a front surface, with at least a first and second item of medical information printed on the front surface. The rotating label medical information system may further comprise an opaque rotating top label covering at least a portion of the front surface of the base label. The opaque rotating top label may be rotatable about the base label. In various embodiments, the opaque rotating top label may have a first transparent window and a second transparent window placed within separate portions of the top label allowing at least the first and second items of medical information to be visible through the first transparent window and the second transparent window.
According to additional exemplary embodiments, the present application may be directed to methods for communicating medical information associated with a container. An exemplary method may comprise adhering a base label having a back surface and a front surface to the container, with at least a first and second item of medical information placed on the front surface of the base label. At least a portion of the front surface of the base label may be covered by an opaque rotating top label. A first transparent window and a second transparent window may be placed within separate portions of the opaque rotating top label, such that at least the first and the second items of medical information may be visible through the first transparent window and the second transparent window.
The present application is directed to rotating label medical information systems for a container. An exemplary illustrative rotating label medical information system may comprise a base label adhered to the container. The base label may have a back surface and a front surface, with at least a first and second item of medical information printed on the front surface. The rotating label medical information system may further comprise an opaque rotating top label covering at least a portion of the front surface of the base label. The opaque rotating top label may be rotatable about the base label. In various embodiments, the opaque rotating top label may have a first transparent window and a second transparent window allowing at least the first and second items of medical information to be visible through the first transparent window and the second transparent window.
As used herein, the leading edge refers to the first edge to be affixed to the object and the trailing edge refers to the second edge to be affixed to the object or the overlapping leading edge. Depending on the orientation of the label and the object when the label is affixed to the object, either edge of the label may be the leading edge. The orientations presented in the figures are for convenience and are not intended to be limiting in any way.
Various embodiments of a back surface 402 of the top label 300 are illustrated in
The base label adhesive 202, 204 and the top label adhesive 404, 406 may be applied in a variety of patterns as can be appreciated by one skilled in the art. The adhesive 202, 204, 404, 406 may be applied in in strips, dots, droplets, circles, rectangles, squares, triangles, lines, and the like, as well as combinations of patterns.
A length of the top label 300 may be selected to be slightly longer than a circumference of the object on which it is placed, such that the top label trailing edge 304 overlaps the top label leading edge 302, and the top label trailing edge 304 is affixed to the top label leading edge 302. In various embodiments, the length of the top label 300 may be selected to be approximately the same as the circumference of the object on which it is placed, such that both the leading edge 302 and the trailing edge 304 do not overlap and are affixed to the base label front surface 108.
In various embodiments, the top label 300 may be rotatable about the base label 100, as discussed below. In these embodiments, the upper label panel 508 and lower label panel 510 may function to restrict upward and downward movement of the top label 300 in relation to the container 500 such that the top label 300 generally remains in a position covering at least a portion of the base label 100.
In various embodiments as illustrated in
In various embodiments, the base label adhesive strips 202, 204 may comprise a permanent adhesive. In general, a permanent adhesive is one that does not readily release from a surface to which it adheres after the adhesive dries or cures. Using the base label 100 as an example, the permanent adhesive 202, 204 will tend not to release from the recessed surface 512, nor will it tend to release the base label leading edge 102 or trailing edge 104 once dried or cured. In order to remove the base label from the recessed surface 512, the base label 100 may have to be torn from the adhesive, or the adhesive layer 202, 204 may have to be fractured which may leave some of the adhesive on the recessed surface 512 and some of the adhesive on the base label leading edge 102 or trailing edge 104. Once the surfaces affixed with the permanent adhesive are separated, they may not be reattached.
In
One of at least three types of adhesive may be used for the top label leading edge adhesive 404. A first type of adhesive is the permanent adhesive as described above for the base label 100. When a permanent adhesive is used for the top label leading edge adhesive 404, the top label leading edge generally cannot be detached without inflicting damage to one or both of the top label 300 or the base label 100. This may be desirable for various embodiments where the top label 300 is not intended to be removed from the container 500.
A second type of adhesive that may be used for the top label leading edge adhesive 404 is a releasable adhesive. A releasable adhesive is one that will release from a surface to which it is attached once a sufficient mechanical force is applied. A releasable adhesive may be used, for example, when the top label back surface 402 comprises a coupon for a subsequent purchase of a product. The releasable adhesive may allow the consumer to easily remove the top label 300 for later use. In various embodiments, the releasable adhesive may be a breakaway adhesive. A breakaway adhesive may have limited ability to withstand shear stresses. Shear stresses may cause the adhesive bond created between the label (e.g., top label 300) and the surface to which it is affixed (e.g., the base label 100 or container 500) to fail along the adhesive. In general, a releasable or breakaway adhesive may not re-attach to a surface once removed.
A third type of adhesive that may be used for the top label leading edge adhesive 404 is a resealable adhesive. A resealable adhesive may release from a surface to which it is attached once a sufficient mechanical force is applied, similar to the releasable adhesive described above. However, the resealable adhesive may be re-attached to a surface by applying pressure. A resealable adhesive may be desirable when the top label back surface 402 or the base label front surface 108 comprise information that may be needed only on occasion. Thus, the consumer or user may detach the top label 300 when the information is needed, then re-attach the top label 300.
In various embodiments, the top label trailing edge adhesive 406 may be a releasable adhesive or a resealable adhesive, depending on the intended use of the top label 300. As described above, if the surfaces 108, 402 comprise information that is intended to stay with the container, the top label trailing edge adhesive 406 may be a resealable adhesive. In contrast, if the top label 300 is intended to be removed from the container 500, a releasable adhesive may be desirable.
Once the top label 300 is in position on the container 1000 as illustrated in
One skilled in the art will readily recognize that labels may be applied to containers using a variety of methods and that there may be a variety of single-label and multi-label systems other than those described above. Any such application methods or label systems may be used with the present disclosure. The above descriptions are exemplary and not to be construed as limiting in any way. Examples of other application methods and label systems may be disclosed in U.S. Pat. Nos. 5,884,421, 6,086,697, 6,237,269, 6,402,872, 6,631,578, 6,649,007, 7,087,298, and 7,172,668.
The graphical illustration section 1205 may comprise a plurality of individual first illustrations 1215-1240 (or images) representing at least a first item of medical information such as medical conditions, effects of taking medication, effects of not taking medication, potential drug interactions, or any other information the manufacturer of the medication in the container 1405 may desire to present to the consumer. In various embodiments, the first illustrations 1215-1240 may indicate progressively improving conditions related to taking the medication or progressively worsening conditions related to not taking the medication. In various embodiments, the first illustrations 1215-1240 may comprise a portion of a graphical representation that, when interacting with the top label 300 as described in detail below, forms a complete visual aid. The first illustrations 1215-1240 may be depicted in any color or combination of colors and may include any combination of alphanumeric characters.
In various embodiments, the text information section 1210 may comprise a plurality of individual messages 1245-1265 representing at least a second item of medical information, such as instructions, explanations, facts, or other information that coincide with and may be related to at least one of the first illustrations 1215-1240 in the graphical illustration section 1205. While
The base label 100 may have a blank portion 1270 along the leading edge 102 that is essentially void of any base label indicia 106. As described previously, the trailing edge 104 may overlap the leading edge 102 when the base label 100 is applied to the container 1405. The blank portion 1270 provides a space for attachment of the trailing edge 104 without obscuring any of the base label indicia 106.
As illustrated in
In various embodiments, at least one of the messages 1245-1265 (in this example, message 1245) may be revealed simultaneously in the transparent section 1305 of the window 1002. The message 1245-1265 may compliment the visual aid created by the first illustration 1215-1240 and the opaque markings of the semi-transparent section 1310 of the window 1002. In the example of
As one skilled in the art will readily recognize, any type of visual representation comprising overlapping images or side-by-side images is within the scope of the present disclosure.
As described previously for
The semi-transparent section 1310 of the window 1002 of the top label 300 may comprise opaque markings that define a second illustration (for example, in
Further rotation of the top label 300 in the direction indicated by the arrow in
In various embodiments, the first illustrations 2005-2025 may be printed in a variety of colors to further enhance the effect of the visual aid. For example, various shades of red could be used for each of the first illustrations 2005-2025 to depict different intensities of sinus inflammation. In addition, the intensity of the shading may vary from one first illustration 2005-2025 to the other to depict the intensity of the sinus inflammation. For example, the first illustration 2005 may be depicted in a dark and intense shade of red to indicate a severe case of sinus infection, while the first illustration 2025 may be depicted in a light shade of red that is only marginally visible to indicate the relieving effects of the medication.
In various embodiments as illustrated in
The top label 300 may comprise a dual ply (or multi-ply) construction in which a ply in contact with the base label 100 is a material selected for low sliding friction characteristics. The low sliding friction characteristics may enhance the ease of rotating and sliding the top label 300 about the base label 100. In various embodiments, the top label 300 ply in contact with the base label 100 may be coated with a substance to impart the low sliding friction characteristics.
In various embodiments, all or a portion of the base label indicia 106 may be imprinted, embossed, or molded directly on an outer surface of the container 1405 in place of all or a portion of the base label 100. The imprinting or embossing may be carried out using any printing or image transfer method known in the art. In various embodiments, the printing or image transfer method may be an offset process in which an image is transferred from a plate to an intermediate carrier, then to the outer surface of the container 1405. The offset process may also involve lithographic techniques. Other printing or image transfer methods may comprise, for example, flexography, pad printing, relief printing, rotogravure, screen printing, and electrophotography. According to various embodiments, the base label indicia 106 may be digitally printed on the outer surface of the container 1405 using, for example, inkjet printing or laser printing. Chemical printing technologies, such as blueprint or diazo print may also be used in various embodiments.
Spatially relative terms such as “under”, “below”, “lower”, “over”, “upper”, and the like, are used for ease of description to explain the positioning of one element relative to a second element. These terms are intended to encompass different orientations of the device in addition to different orientations than those depicted in the figures. Further, terms such as “first”, “second”, and the like, are also used to describe various elements, regions, sections, etc. and are also not intended to be limiting. Like terms refer to like elements throughout the description.
As used herein, the terms “having”, “containing”, “including”, “comprising”, and the like are open ended terms that indicate the presence of stated elements or features, but do not preclude additional elements or features. The articles “a”, “an” and “the” are intended to include the plural as well as the singular, unless the context clearly indicates otherwise.
The present invention may be carried out in other specific ways than those herein set forth without departing from the scope and essential characteristics of the invention. The present embodiments are, therefore, to be considered in all respects as illustrative and not restrictive, and all changes coming within the meaning and equivalency range of the appended claims are intended to be embraced therein.
The present application claims priority to provisional U.S. Patent Application Ser. No. 61/524,254, filed on Aug. 16, 2011, titled “Method and Device for Illustrating a Medical Condition and the Results from Taking the Medication Within the Packaging,” which is hereby incorporated by reference in its entirety.
Number | Name | Date | Kind |
---|---|---|---|
332208 | Noel | Dec 1885 | A |
736035 | Stevenson | Aug 1903 | A |
1054826 | Cole | Mar 1913 | A |
1064576 | Washburn | Jun 1913 | A |
1145367 | Herter | Jul 1915 | A |
1312611 | Chess | Aug 1919 | A |
1317660 | Carlson | Sep 1919 | A |
1334031 | Hahn | Mar 1920 | A |
1387625 | Stein | Aug 1921 | A |
1486313 | Van Antwerp | Mar 1924 | A |
2013615 | Haviland Fontan Le Roy | Sep 1935 | A |
2013616 | Rettenmeyer | Sep 1935 | A |
2069609 | Hanson | Feb 1937 | A |
2129364 | Simons et al. | Sep 1938 | A |
2441607 | Walls | May 1948 | A |
2468000 | Taylor | Apr 1949 | A |
2487274 | Schaffer | Nov 1949 | A |
2504076 | Lindblom | Apr 1950 | A |
2706464 | North | Apr 1955 | A |
2738564 | Guianne | Mar 1956 | A |
2739564 | North | Mar 1956 | A |
2844893 | Keller | Jul 1958 | A |
2860431 | Barnum | Nov 1958 | A |
2931657 | Lewis | Apr 1960 | A |
2935814 | Freeze | May 1960 | A |
2971283 | Parker | Feb 1961 | A |
3233770 | Waters | Feb 1966 | A |
3278182 | Lescher | Oct 1966 | A |
3374911 | White | Mar 1968 | A |
D210767 | Anglada | Apr 1968 | S |
3375954 | Arvid Honkanen et al. | Apr 1968 | A |
3468467 | Amberg | Sep 1969 | A |
3488880 | Taylor | Jan 1970 | A |
3523623 | Dorn | Aug 1970 | A |
3542229 | Beyerlein et al. | Nov 1970 | A |
3604584 | Shank | Sep 1971 | A |
3633781 | Zapata | Jan 1972 | A |
3733002 | Fujio | May 1973 | A |
3750317 | Morgan | Aug 1973 | A |
3766882 | Babbitt, III | Oct 1973 | A |
3779829 | Wolff | Dec 1973 | A |
3865671 | Kronsder | Feb 1975 | A |
3874977 | Pyles | Apr 1975 | A |
3960713 | Carey | Jun 1976 | A |
4044889 | Orentreich et al. | Aug 1977 | A |
4057251 | Jones et al. | Nov 1977 | A |
4072553 | Braker et al. | Feb 1978 | A |
4203240 | Goodwin | May 1980 | A |
4312523 | Haines | Jan 1982 | A |
4318683 | Fishbaugh et al. | Mar 1982 | A |
4381615 | Lonsmin | May 1983 | A |
4405045 | Villa-Real | Sep 1983 | A |
4473429 | Crankshaw | Sep 1984 | A |
4505497 | Katzman | Mar 1985 | A |
4518450 | Warmann | May 1985 | A |
4533586 | Roule et al. | Aug 1985 | A |
4567681 | Fumei | Feb 1986 | A |
4589943 | Kimball et al. | May 1986 | A |
4658974 | Fujita et al. | Apr 1987 | A |
4680080 | Instance | Jul 1987 | A |
4700976 | Loose | Oct 1987 | A |
4724973 | Shah | Feb 1988 | A |
4727667 | Ingle | Mar 1988 | A |
4732411 | Siegel | Mar 1988 | A |
4844760 | Dickey | Jul 1989 | A |
4877119 | Hosking | Oct 1989 | A |
4918604 | Baum | Apr 1990 | A |
4920912 | Kirkling | May 1990 | A |
4955153 | Albrecht et al. | Sep 1990 | A |
D311423 | DeSantis | Oct 1990 | S |
5017261 | Zodrow et al. | May 1991 | A |
5048870 | Mangini et al. | Sep 1991 | A |
5062917 | Zodrow | Nov 1991 | A |
5076613 | Kovacs | Dec 1991 | A |
5078826 | Rogall | Jan 1992 | A |
5116452 | Eder | May 1992 | A |
5154448 | Griffin et al. | Oct 1992 | A |
5207011 | Coulthard | May 1993 | A |
5209367 | Van Musscher et al. | May 1993 | A |
5215622 | Schmelzer | Jun 1993 | A |
5263743 | Jones | Nov 1993 | A |
5264265 | Kaufmann | Nov 1993 | A |
5269085 | Chiapetta et al. | Dec 1993 | A |
5284363 | Gartner et al. | Feb 1994 | A |
5321933 | Seifert et al. | Jun 1994 | A |
5324559 | Brombacher | Jun 1994 | A |
5339998 | Warren | Aug 1994 | A |
5342093 | Weernink | Aug 1994 | A |
5363576 | Piana et al. | Nov 1994 | A |
5370754 | Soloman | Dec 1994 | A |
5403635 | Hoffman | Apr 1995 | A |
5403636 | Crum | Apr 1995 | A |
5405482 | Morrissette et al. | Apr 1995 | A |
5462488 | McKillip | Oct 1995 | A |
5484167 | Donaldson et al. | Jan 1996 | A |
D368234 | Dickinson et al. | Mar 1996 | S |
5525383 | Witkowski | Jun 1996 | A |
5605230 | Marino, Jr. et al. | Feb 1997 | A |
5605730 | Treleaven | Feb 1997 | A |
5639529 | Gozdecki et al. | Jun 1997 | A |
D383038 | Willbrandt | Sep 1997 | S |
D386947 | Lapierre et al. | Dec 1997 | S |
5712021 | Hernandez | Jan 1998 | A |
5727766 | Mayo | Mar 1998 | A |
5727819 | Grosskopf et al. | Mar 1998 | A |
5738382 | Grosskopf et al. | Apr 1998 | A |
5741381 | Dolence et al. | Apr 1998 | A |
5758096 | Barsky et al. | May 1998 | A |
5799525 | Johnson et al. | Sep 1998 | A |
5800893 | Harden | Sep 1998 | A |
5809674 | Key | Sep 1998 | A |
5829789 | Treleaven et al. | Nov 1998 | A |
5830550 | Treleaven et al. | Nov 1998 | A |
5842633 | Nurse | Dec 1998 | A |
5863628 | Barry | Jan 1999 | A |
5883370 | Walker et al. | Mar 1999 | A |
5884421 | Key | Mar 1999 | A |
5953170 | Glancy | Sep 1999 | A |
5975582 | Treleaven | Nov 1999 | A |
6027780 | Treleaven et al. | Feb 2000 | A |
6035568 | Grosskopf et al. | Mar 2000 | A |
6047488 | Tuszkiewicz | Apr 2000 | A |
6048423 | Barrash et al. | Apr 2000 | A |
6057019 | Barry | May 2000 | A |
D428307 | Yeandel | Jul 2000 | S |
6086697 | Key | Jul 2000 | A |
6120637 | Barry | Sep 2000 | A |
6129802 | Key | Oct 2000 | A |
6129959 | Mercer et al. | Oct 2000 | A |
6158612 | Alpert | Dec 2000 | A |
D436499 | Pritchard et al. | Jan 2001 | S |
6212803 | Key | Apr 2001 | B1 |
6213520 | Treleaven et al. | Apr 2001 | B1 |
6237269 | Key | May 2001 | B1 |
6253438 | Jespersen | Jul 2001 | B1 |
6254138 | Rawlings et al. | Jul 2001 | B1 |
6258200 | Kassab | Jul 2001 | B1 |
6267672 | Vance | Jul 2001 | B1 |
D446687 | Furman et al. | Aug 2001 | S |
6270121 | Dolan et al. | Aug 2001 | B1 |
6274236 | Shacklett et al. | Aug 2001 | B1 |
6276533 | Kaplan | Aug 2001 | B1 |
6328832 | Otruba et al. | Dec 2001 | B1 |
6329034 | Pendry et al. | Dec 2001 | B1 |
6360462 | Mengel | Mar 2002 | B1 |
6385878 | Key | May 2002 | B1 |
6398263 | Treleaven et al. | Jun 2002 | B2 |
6402872 | Key | Jun 2002 | B1 |
6413345 | Treleaven | Jul 2002 | B1 |
D461369 | Sims et al. | Aug 2002 | S |
6428639 | Oldenburg et al. | Aug 2002 | B1 |
6431241 | Gonzalo | Aug 2002 | B1 |
6454094 | Salani | Sep 2002 | B1 |
6550171 | De Werra et al. | Apr 2003 | B1 |
6550512 | Yang | Apr 2003 | B2 |
6561246 | Yang | May 2003 | B2 |
6575216 | Yang | Jun 2003 | B2 |
6581773 | Kaplan | Jun 2003 | B2 |
6616189 | Raming | Sep 2003 | B2 |
6622878 | Frey | Sep 2003 | B1 |
6631578 | Key | Oct 2003 | B2 |
6649007 | Key | Nov 2003 | B1 |
6669804 | Pendry et al. | Dec 2003 | B2 |
6722568 | Blanford et al. | Apr 2004 | B2 |
6737137 | Franko, Sr. et al. | May 2004 | B2 |
6752431 | Matthews et al. | Jun 2004 | B1 |
6755442 | Franko, Sr. et al. | Jun 2004 | B2 |
6779480 | Zamjahn | Aug 2004 | B2 |
6786515 | Franko, Sr. | Sep 2004 | B2 |
6793075 | Jeter | Sep 2004 | B1 |
6793755 | Schaupp et al. | Sep 2004 | B2 |
6811640 | Franko, Sr. | Nov 2004 | B2 |
6904867 | Zamjahn | Jun 2005 | B2 |
7010877 | Geary | Mar 2006 | B2 |
D526847 | Freeman | Aug 2006 | S |
7087298 | Key | Aug 2006 | B2 |
D527583 | Freeman | Sep 2006 | S |
D533748 | Bresler | Dec 2006 | S |
7172220 | Franko, Sr. | Feb 2007 | B2 |
7172668 | Key | Feb 2007 | B2 |
7179514 | Olsen et al. | Feb 2007 | B2 |
D545429 | Hays | Jun 2007 | S |
7325510 | Giewercer | Feb 2008 | B2 |
7601410 | Matthews et al. | Oct 2009 | B2 |
7621231 | McNeely | Nov 2009 | B2 |
7628427 | Adler et al. | Dec 2009 | B2 |
7782479 | Handa et al. | Aug 2010 | B2 |
7875142 | Matthews et al. | Jan 2011 | B2 |
7886909 | Robinson | Feb 2011 | B2 |
7926851 | Kaufman | Apr 2011 | B2 |
8037628 | Kaufman | Oct 2011 | B2 |
8043993 | Roth et al. | Oct 2011 | B2 |
D649396 | Wilkens et al. | Nov 2011 | S |
8142596 | Valenti, Jr. et al. | Mar 2012 | B1 |
8245752 | Lingier et al. | Aug 2012 | B2 |
8272562 | Ziegler | Sep 2012 | B2 |
8413884 | Lim et al. | Apr 2013 | B2 |
8424761 | Yanagi | Apr 2013 | B2 |
D682088 | de Urquijo Carmona | May 2013 | S |
8479919 | Kaplan et al. | Jul 2013 | B2 |
8709198 | Key | Apr 2014 | B2 |
8727220 | Key | May 2014 | B2 |
D706624 | Key | Jun 2014 | S |
D706625 | Key | Jun 2014 | S |
8814217 | Key | Aug 2014 | B2 |
20010004152 | Treleaven et al. | Jun 2001 | A1 |
20010017181 | Otruba et al. | Aug 2001 | A1 |
20010025442 | Key | Oct 2001 | A1 |
20010045741 | Shacklett et al. | Nov 2001 | A1 |
20010050242 | Kaplan | Dec 2001 | A1 |
20020015813 | Pendry et al. | Feb 2002 | A1 |
20020017784 | Merry et al. | Feb 2002 | A1 |
20020029635 | Kremen | Mar 2002 | A1 |
20020038685 | Key | Apr 2002 | A1 |
20020096261 | Yang | Jul 2002 | A1 |
20020096262 | Yang | Jul 2002 | A1 |
20020096264 | Yang | Jul 2002 | A1 |
20020104613 | Key | Aug 2002 | A1 |
20020130182 | Mondie | Sep 2002 | A1 |
20020139292 | Giewercer | Oct 2002 | A1 |
20020185212 | Schaupp et al. | Dec 2002 | A1 |
20020193225 | Raming | Dec 2002 | A1 |
20030006606 | Franko, Sr. et al. | Jan 2003 | A1 |
20030012911 | Campbell | Jan 2003 | A1 |
20030015105 | Dewig et al. | Jan 2003 | A1 |
20030030270 | Franko, Sr. et al. | Feb 2003 | A1 |
20030091819 | Franko, Sr. | May 2003 | A1 |
20030118768 | Sellars | Jun 2003 | A1 |
20030137145 | Fell et al. | Jul 2003 | A1 |
20030175463 | Olsen et al. | Sep 2003 | A1 |
20030189490 | Hogerton et al. | Oct 2003 | A1 |
20030201064 | Treleaven et al. | Oct 2003 | A1 |
20040108237 | McClintock | Jun 2004 | A1 |
20040123565 | Rice et al. | Jul 2004 | A1 |
20040166277 | Key | Aug 2004 | A1 |
20040188998 | Henthorn | Sep 2004 | A1 |
20040197513 | Shacklett et al. | Oct 2004 | A1 |
20040207193 | Franko, Sr. | Oct 2004 | A1 |
20040247863 | Scott | Dec 2004 | A1 |
20050038558 | Keene | Feb 2005 | A1 |
20050056203 | Giewercer | Mar 2005 | A1 |
20050097004 | Masse Blume | May 2005 | A1 |
20050120600 | Harman | Jun 2005 | A1 |
20050181165 | Franko | Aug 2005 | A1 |
20050183982 | Giewercer | Aug 2005 | A1 |
20050190914 | Chen et al. | Sep 2005 | A1 |
20050209870 | Alden | Sep 2005 | A1 |
20060029761 | Matthews et al. | Feb 2006 | A1 |
20060032923 | Krupa | Feb 2006 | A1 |
20060078701 | Glasier | Apr 2006 | A1 |
20060145471 | Franko | Jul 2006 | A1 |
20060249950 | Kenney et al. | Nov 2006 | A1 |
20070029787 | Loftin et al. | Feb 2007 | A1 |
20070034103 | Kaufman | Feb 2007 | A1 |
20070043530 | O'Rourke | Feb 2007 | A1 |
20070119542 | Williams et al. | May 2007 | A1 |
20070209753 | Gonzalez et al. | Sep 2007 | A1 |
20070209755 | Smith | Sep 2007 | A1 |
20070213214 | Roth et al. | Sep 2007 | A1 |
20070221319 | Morgan | Sep 2007 | A1 |
20070222205 | Handa et al. | Sep 2007 | A1 |
20070252379 | Bethune et al. | Nov 2007 | A1 |
20070299693 | Jung et al. | Dec 2007 | A1 |
20080003391 | Franko et al. | Jan 2008 | A1 |
20080003410 | Shacklett et al. | Jan 2008 | A1 |
20080010874 | Londino | Jan 2008 | A1 |
20080014344 | Fort et al. | Jan 2008 | A1 |
20080073902 | Franko | Mar 2008 | A1 |
20080121688 | Harrop | May 2008 | A1 |
20080176955 | Heck et al. | Jul 2008 | A1 |
20080208694 | Baggott | Aug 2008 | A1 |
20080233405 | Dronzek Jr. | Sep 2008 | A1 |
20080303264 | Kaufman | Dec 2008 | A1 |
20080303265 | Kaufman | Dec 2008 | A1 |
20090236023 | Lingier et al. | Sep 2009 | A1 |
20090255623 | Bagung et al. | Oct 2009 | A1 |
20090264815 | Grogan, Jr. | Oct 2009 | A1 |
20090265188 | Lamy et al. | Oct 2009 | A1 |
20090294521 | de la Huerga | Dec 2009 | A1 |
20100043267 | Sterling | Feb 2010 | A1 |
20100044438 | Chen et al. | Feb 2010 | A1 |
20100084077 | Matthews et al. | Apr 2010 | A1 |
20100101681 | Kramer et al. | Apr 2010 | A1 |
20100228615 | Hays | Sep 2010 | A1 |
20100240133 | Brivanlou et al. | Sep 2010 | A1 |
20100295916 | Kaufman | Nov 2010 | A1 |
20100300599 | Fort et al. | Dec 2010 | A1 |
20100307947 | Marden et al. | Dec 2010 | A1 |
20110061802 | Raming | Mar 2011 | A1 |
20110151115 | Lingier | Jun 2011 | A1 |
20110169602 | Gaffney | Jul 2011 | A1 |
20110185606 | Londino | Aug 2011 | A1 |
20110233095 | Seidl | Sep 2011 | A1 |
20120006712 | Kaplan et al. | Jan 2012 | A1 |
20120010299 | Kaplan et al. | Jan 2012 | A1 |
20120037299 | Baeta et al. | Feb 2012 | A1 |
20120085828 | Ziegler | Apr 2012 | A1 |
20120118503 | Lorence et al. | May 2012 | A1 |
20120125526 | Key | May 2012 | A1 |
20120175336 | Miller et al. | Jul 2012 | A1 |
20120268837 | Rittenburg et al. | Oct 2012 | A1 |
20120279632 | Lingier et al. | Nov 2012 | A1 |
20120292219 | Terwilliger et al. | Nov 2012 | A1 |
20130025175 | Key | Jan 2013 | A1 |
20130025529 | Key | Jan 2013 | A1 |
20130026056 | Key | Jan 2013 | A1 |
20130026747 | Key | Jan 2013 | A1 |
20130033031 | Key | Feb 2013 | A1 |
20130036634 | Key | Feb 2013 | A1 |
20130036641 | Key | Feb 2013 | A1 |
20130037619 | Key | Feb 2013 | A1 |
20130043157 | Key | Feb 2013 | A1 |
20130062239 | Key | Mar 2013 | A1 |
20130129971 | Key et al. | May 2013 | A1 |
20140076766 | Key | Mar 2014 | A1 |
20140210198 | Key | Jul 2014 | A1 |
20140224889 | Key | Aug 2014 | A1 |
20140339120 | Key | Nov 2014 | A1 |
Number | Date | Country |
---|---|---|
932891 | Apr 2002 | AT |
1165378 | Sep 2004 | AT |
723118 | Nov 2000 | AU |
932891 | Apr 2002 | BE |
1165378 | Sep 2004 | BE |
932891 | Apr 2002 | CH |
1165378 | Sep 2004 | CH |
103890826 | Jun 2014 | CN |
69711903.3-08 | Apr 2002 | DE |
1165378 | Sep 2004 | DE |
85214 | Mar 1958 | DK |
932891 | Apr 2002 | DK |
285514 | Oct 1988 | EP |
932891 | Apr 2002 | EP |
1165378 | Sep 2004 | EP |
2742501 | Jun 2014 | EP |
932891 | Apr 2002 | ES |
965522 | Sep 1950 | FR |
1114750 | Apr 1956 | FR |
1347102 | Nov 1963 | FR |
2460260 | Jan 1981 | FR |
285514 | Oct 1988 | FR |
2613519 | Oct 1988 | FR |
2677786 | Dec 1992 | FR |
932891 | Apr 2002 | FR |
1165378 | Sep 2004 | FR |
932891 | Apr 2002 | GB |
1039770 | May 2002 | HK |
1021056 | Jul 2002 | HK |
932891 | Apr 2002 | IE |
1165378 | Sep 2004 | IE |
327286 | Jul 1935 | IT |
932891 | Apr 2002 | IT |
204456 | Sep 2002 | MX |
225535 | Jan 2005 | MX |
227727 | May 2005 | MX |
932891 | Apr 2002 | NL |
334683 | Nov 1999 | NZ |
1565 | Jul 1888 | SE |
932891 | Apr 2002 | SE |
WO9819289 | May 1998 | WO |
WO0048161 | Aug 2000 | WO |
WO03017174 | Feb 2003 | WO |
WO2007020628 | Feb 2007 | WO |
WO2012071355 | May 2012 | WO |
WO2013015838 | Jan 2013 | WO |
WO2013015839 | Jan 2013 | WO |
WO2013016364 | Jan 2013 | WO |
WO2013016461 | Jan 2013 | WO |
WO2013019907 | Feb 2013 | WO |
WO2013022495 | Feb 2013 | WO |
WO2013022508 | Feb 2013 | WO |
WO2013023221 | Feb 2013 | WO |
WO2013025947 | Feb 2013 | WO |
WO2013039578 | Mar 2013 | WO |
WO2013043618 | Mar 2013 | WO |
WO2014047077 | Mar 2014 | WO |
Entry |
---|
International Search Report and Written Opinion mailed May 25, 2012 in Patent Cooperation Treaty Application No. PCT/US12/22609, filed Jan. 25, 2012. |
International Search Report and Written Opinion mailed May 23, 2012 in Patent Cooperation Treaty Application No. PCT/US2012/022610, filed Jan. 25, 2012. |
International Search Report and Written Opinion mailed Oct. 9, 2012 in Patent Cooperation Treaty Application No. PCT/US2012/048021, filed Jul. 24, 2012. |
International Search Report and Written Opinion mailed Oct. 23, 2012 in Patent Cooperation Treaty Application No. PCT/US2012/050643, filed Aug. 13, 2012. |
International Search Report and Written Opinion mailed Nov. 30, 2012 in Patent Cooperation Treaty Application No. PCT/US2012/055948, filed Sep. 18, 2012. |
International Search Report and Written Opinion mailed Jul. 26, 2012 in Patent Cooperation Treaty Application No. PCT/US2012/037395, filed May 10, 2012. |
International Search Report and Written Opinion mailed Oct. 16, 2012 in Patent Cooperation Treaty Application No. PCT/US2012/048201, filed Jul. 25, 2012. |
International Search Report and Written Opinion mailed Jul. 9, 2012 in Patent Cooperation Treaty Application No. PCT/US2012/031670, filed Mar. 30, 2012. |
International Search Report and Written Opinion mailed Oct. 23, 2012 in Patent Cooperation Treaty Application No. PCT/US2012/051228, filed Aug. 16, 2012. |
International Search Report and Written Opinion mailed Oct. 16, 2012 in Patent Cooperation Treaty Application No. PCT/US2012/049234, filed Aug. 1, 2012. |
International Search Report and Written Opinion mailed Aug. 27, 2012 in Patent Cooperation Treaty Application No. PCT/US2012/040301, filed May 31, 2012. |
Newswire, “AccuDial(R) Pharmaceutical, Inc. can put an end to underdosing and overdosing with new line of children's over-the-counter medications”, Jul. 8, 2010 [retrieved Dec. 12, 2013]. Retrieved from Internet: <http://www.newswire.ca/en/story/646945/accudial-r-pharmaceutical-inc-can-put-an-end-to-underdosing-and-overdosing-with-new-line-of-children-s-over-the-counter-medications>. |
Accudial Pharmaceutical, Inc. company website, www.accuratedose.com, Oct. 30, 2010 [retrieved Aug. 7, 2012). Retrieved from Internet: <http://web.archive.org/web/20101030115353/http://www.accuratedose.com.ca—english/home>. |
Anonymous, “Chest congestion (guaifenesin) liquid”, Internet article, http://dailymed.nlm.nih.gov/dailymed/druginfo.cfm?id=25295., (Oct. 26, 2009). |
Anonymous, “Pharmaceutical & medical packaging news”, The packaging magazine for the healthcare industry, 16:12:76-78, Internet article, http://www.accuratedose.com/corporate/assets/pdf/PMP—MagReprinIDec08.pdf, (Dec. 12, 2008). |
A. Abramson, “Start-up has twist on safe doses for kids”, Internet article, http://www.accuratedose.com/corporate/assets/pdf/50840—ACC—PBP—Article. pdf, (Jul. 27, 2009). |
Anonymous, “Chest congestion guaifenesin oral solution expectorant”, Internet article, http://accuratedose.com/us—english/producUnformation/chest—congestion.html, (Aug. 24, 2011). |
International Search Report and Written Opinion mailed Apr. 2, 2012 in Patent Cooperation Treaty Application No. PCT/US2011/061739, filed Nov. 21, 2011. |
International Search Report and Written Opinion mailed Feb. 28, 2014 in Patent Cooperation Treaty Application No. PCT/US2013/060220, filed Sep. 17, 2013. |
Number | Date | Country | |
---|---|---|---|
20130043157 A1 | Feb 2013 | US |
Number | Date | Country | |
---|---|---|---|
61524254 | Aug 2011 | US |